All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.~Primary objective:~To observe the safety of SIR-Spheres® microspheres therapy (SIRT)by,~Adverse events and serious adverse events (non-specific and radiation specific)~Changes in liver function parameters~To observe the efficacy of SIR-Spheres® microspheres therapy by, assessing the best overall response rate after SIRT~Secondary objectives:~To observe the efficacy of SIRT by,~Overall survival (OS)~Overall/objective response rate (ORR)~Time-to-progression~Time-to-liver progression~Progression-free survival~To observe the changes in clinical presentation after SIRT by,~ECOG score~Child-Pugh score~Percentage of subjects with down-staging or down-sizing of treated lesion to resection, transplantation, or radiofrequency ablation (RFA)~To observe the practice pattern of SIRT by,~Median dosage (GBq)~Number of SIRT sessions received by subjects~Exploratory objectives:~To explore prognostic factors for disease progression after SIRT by comparing the following parameters:~Number of tumors in subjects prior to SIRT~Median tumor size in subjects prior to SIRT~Location of tumor in subjects treated with SIRT (hepatic segment or lobe)~Number of prior TACE treatment in subjects~Antiviral therapy subjects HCC
All study objectives will be assessed in HCC patients or colorectal cancer patients with secondary metastases in the liver, respectively.